首页> 外文期刊>The lancet oncology >Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment.
【24h】

Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment.

机译:双膦酸盐相关的骨坏死:双膦酸盐治疗的长期并发症。

获取原文
获取原文并翻译 | 示例
           

摘要

We present current knowledge of bisphosphonate-associated osteonecrosis, a new oral complication in oncology. It was first described in 2003, and hundreds of cases have been reported worldwide. The disorder affects patients with cancer on bisphosphonate treatment for multiple myeloma or bone metastasis from breast, prostate, or lung cancer. Bisphosphonate-associated osteonecrosis is characterised by the unexpected appearance of necrotic bone in the oral cavity. Osteonecrosis can develop spontaneously or after an invasive surgical procedure such as dental extraction. Patients might have severe pain or be asymptomatic. Symptoms can mimic routine dental problems such as decay or periodontal disease. Intravenous use of pamidronate and zoledronic acid is associated with most cases. Other risk factors include duration of bisphosphonate treatment (ie, 36 months and longer), old age in patients with multiple myeloma, and a history of recent dental extraction. We also discuss pathobiology, clinical features, management, and future directions for the disorder.
机译:我们介绍了双膦酸盐相关的骨坏死,肿瘤学上的一种新的口腔并发症的最新知识。它于2003年首次被描述,并且全世界已经报道了数百例。这种疾病会影响接受双膦酸盐治疗的癌症患者的多发性骨髓瘤或乳腺癌,前列腺癌或肺癌的骨转移。双膦酸盐相关的骨坏死的特征是在口腔中意外出现坏死骨。骨坏死可以自发发展,也可以在侵入性外科手术(例如拔牙)后发展。患者可能有严重的疼痛或无症状。症状可以模仿常规的牙齿问题,例如蛀牙或牙周疾病。多数情况下静脉使用帕米膦酸和唑来膦酸。其他危险因素包括双磷酸盐治疗的持续时间(即36个月或更长时间),多发性骨髓瘤患者的高龄以及最近的拔牙史。我们还将讨论该疾病的病理生物学,临床特征,治疗和未来方向。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号